Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations
NCT04671849Phase 1Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM1803-1A in solid tumor (8 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Number of participants with adverse events at 5 years, Severity of adverse events at 5 years and 7 more. Started Dec 2020; status: terminated.
02
Drugs
SIM1803-1A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04671849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04671849.